stella
beta
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer β Stella
Recruiting
Back to Solid Tumors trials
Phase 1 β Early testing in a small group of people (usually 20β80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(5 sites)
Japan
National Cancer Center Hospital East, Kashiwa, Chiba
Kanagawa Cancer Center, Yokohama, Kanagawa
Niigata University Medical and Dental Hospital, Niigata, Niigata
National Cancer Center Hospital, ChΕ«Ε, Tokyo
University of Yamanashi Hospital, ChΕ«Ε, Yamanashi
View full record on ClinicalTrials.gov